Tacrolimus is an immunosuppressive drug used along with several other drugs for preventing cellular rejection after an organ transplantation. Tacrolimus suppresses the activity of the immune system and avoids it from attacking the newly transplanted organ. Tacrolimus is available in the form of granules or capsules for oral suspension, extended-release tablet are used for oral administration and also in the form of extended-release capsule. It is mostly used for treating severe refractory uveitis, skin disorder vitiligo, bone marrow transplants and severe atopic dermatitis.
Global tacrolimus market, is forecast to be valued at US$ 6,485.3 Mn in 2022 and is estimated to exhibit a CAGR of 4.7% over the forecast period.
Request Here For The Sample Copy Of The Report @ https://www.coherentmarketinsights.com/insight/request-sample/2298
Impact of COVID-19:
The pandemic and strict lockdowns in several nation worldwide have affected the financial status of many businesses in all sectors, along with the private healthcare sector. Supply chains of the healthcare sector were also impacted owing to the pandemic in many regions. COVID-19 has affected the private healthcare sector significantly.
The pandemic caused a negative impact on the global tacrolimus market, owing to the growing risk of getting infected with COVID-19 during organ transplants. However, organ transplant recipients can be at the risk of getting infected with COVID-19 as they are immunosuppressed and they are less likely to generate immune responses to vaccination.
Furthermore, reduced rate of organ transplants during the pandemic had a negative impact on the global tacrolimus market during the forecast period. For instance, The Transplantation Society published an article in April 2022, mentioning that the pandemic resulted in a global decline of 16% in the transplant activity in 2020. This impacted many kidney transplants and living donor programs.
Furthermore, increasing number of new organ transplant centers being established is estimated to fuel growth of the global tacrolimus market during the forecast period. For instance, Sahyadri Super Speciality Hospital has initiated an organ transplant center at taluka level in Karad, India, in November 2021. This transplant center will carry out pancreas, liver and kidney transplants.
Rising product launches by major players is anticipated to augment growth of the global tacrolimus market during the forecast period. For instance, Astellas Pharma Inc., declared the launch of PROGRAF granules in March 2019. PROGRAF has to be used along with other immunosuppressant in order to avoid organ rejection in patients having heart, kidney or liver transplant. PROGRAF granules are mostly given to children having trouble in swallowing capsules.
- The global tacrolimus market is estimated to exhibit a CAGR of 4.7% over the forecast period, due to the rising research activities being carried out on tacrolimus for determining its applications and use in immunosuppression. For instance, the journal Frontiers Media S.A., published an article in November 2021, stating that researchers from the Rajiv Gandhi Centre for Biotechnology in Kerala, India, have designed a new way to determine the optima dose of tacrolimus, which is an immunosuppressant drug, to be given to a patient undergoing kidney transplant. This study was focusing on giving tacrolimus to liver, kidney or heart tranpslnt patients in order to minimize organ rejection.
- The hospital segment, among end users in the global tacrolimus market is anticipated to witness significant growth over the forecast period, due to rising approvals by regulatory authorities for initiating organ transplant facilities in the hospitals. For instance, King George’s Medical University, is a hospital, medical university and a medical school in Lucknow, India has gained approval from Directorate of Medical Education and Training in March 2022, for initiating the kidney transplant program in the hospital.
- North America, among regions in the global tacrolimus market is anticipated to witness robust growth over the forecast period, due to rising product launches by major players. For instance, Biocon declared the launch of Tacrolimus capsules in December 2020, in the U.S. It is an immunosuppressant, calcineurin inhibitor, used in patients during organ transplant which minimizes the organ rejection ability of the body.
Ask For Discount Before Purchasing This Business Report : https://www.coherentmarketinsights.com/insight/request-discount/2298
Key players active in the global tacrolimus market are Vibcare Pharma Pvt. Ltd, Novartis AG, Lupin Limited, Mylan N.V., Glenmark Pharmaceuticals Ltd., Astellas Pharma Inc., Senju Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories Ltd., Abbott and Pfizer Inc.
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Tacrolimus Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Tacrolimus Industry Impact
Chapter 2 Global Tacrolimus Competition by Types, Applications, and Top Regions and Countries
2.1 Global Tacrolimus (Volume and Value) by Type
2.3 Global Tacrolimus (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Tacrolimus Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 North America Tacrolimus Market Analysis
Chapter 6 East Asia Tacrolimus Market Analysis
Chapter 7 Europe Tacrolimus Market Analysis
Chapter 8 South Asia Tacrolimus Market Analysis
Chapter 9 Southeast Asia Tacrolimus Market Analysis
Chapter 10 Middle East Tacrolimus Market Analysis
Chapter 11 Africa Tacrolimus Market Analysis
Chapter 12 Oceania Tacrolimus Market Analysis
Chapter 13 South America Tacrolimus Market Analysis
Chapter 14 Company Profiles and Key Figures in Tacrolimus Business
Chapter 15 Global Tacrolimus Market Forecast (2022-2028)
Chapter 16 Conclusions
Direct Buy This Premium Research Report, Click Here @ https://www.coherentmarketinsights.com/insight/buy-now/2298
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027